II
BCRX icon

Inspire Investing’s BioCryst Pharmaceuticals BCRX Stock Holding History

Inspire Investing’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$513K Sell
53,879
-6,170
-10% -$47.9K 0.03% 734
2025
Q4 		$468K Buy
60,049
+124
+0.2% +$896 0.04% 473
2025
Q3 		$455K Buy
59,925
+16,716
+39% +$139K 0.04% 517
2025
Q2 		$387K Sell
43,209
-2,692
-6% -$25.1K 0.04% 672
2025
Q1 		$344K Sell
45,901
-7,578
-14% -$61.1K 0.04% 491
2024
Q4 		$402K Sell
53,479
-104,529
-66% -$794K 0.05% 450
2024
Q3 		$1.2M Buy
158,008
+100,458
+175% +$764K 0.12% 178
2024
Q2 		$356K Sell
57,550
-11,916
-17% -$65.8K 0.04% 396
2024
Q1 		$353K Buy
69,466
+6,141
+10% +$34.5K 0.04% 782
2023
Q4 		$379K Buy
63,325
+20,255
+47% +$117K 0.04% 772
2023
Q3 		$305K Sell
43,070
-1,513
-3% -$10.9K 0.04% 747
2023
Q2 		$314K Buy
44,583
+12,234
+38% +$98.2K 0.04% 590
2023
Q1 		$270K Buy
32,349
+11,559
+56% +$111K 0.03% 767
2022
Q4 		$239K Buy
20,790
+4,402
+27% +$54.9K 0.03% 367
2022
Q3 		$206K Buy
+16,388
New +$211K 0.03% 593

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Inspire Investing's BCRX Position: Q1 2026 in Review

Inspire Investing reduced its BioCryst Pharmaceuticals (BCRX) stake by 10% in Q1 2026, selling an estimated $47.9K and leaving 53,879 shares worth $513K. The position accounts for 0.03% of the portfolio, ranked #734.

Inspire Investing first reported a position in BCRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.2M in Q3 2024. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Inspire Investing held 53,879 shares of BioCryst Pharmaceuticals worth $513K as of Q1 2026.
  • Inspire Investing sold 6,170 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $47.9K.
  • BioCryst Pharmaceuticals made up 0.03% of Inspire Investing's portfolio in Q1 2026, its #734 holding.
  • Inspire Investing first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Inspire Investing's BioCryst Pharmaceuticals position peaked at $1.2M in Q3 2024.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Inspire Investing's 13F filing for Q1 2026, filed 23 Apr 2026.